21-Feb-2023 | Market Research Store
A biomarker is a substance that can be introduced among organisms to inspect organ functions or other aspects of their health. A biomarker is objectively evaluated and measured as an indication of typical pathogenic processes, biological processes, or pharmacologic responses to therapeutic interventions. Biomarkers are genetic molecules produced either by human tissues or tumor cells in response to cancer. These molecules are then evaluated and measured as a mark of cancerous processes inside the body. Biomarkers are widely used in the management and detection of diseases in the patient population.
The growing prevalence of cancer and cardiovascular diseases, increasing healthcare expenditure for the diagnosis and treatment of chronic diseases are projected to fuel the global biomarkers market. Furthermore, the encouraging initiative by government and high adoption of technically advanced products will also boost the biomarker market in the future.
The global cancer biomarkers market is fragmented based on biomarker type, application, and disease. Based on biomarker type, the biomarkers market is categorized into safety, validation, and efficacy biomarkers. Based on application, the biomarkers market includes personalized medicine, diagnostic, drug discovery and development, and others. By disease, the biomarkers market comprises immunological diseases, cancer, neurological diseases, cardiovascular diseases, and others.
North America dominated the biomarkers market globally in 2018 and is likely to remain dominant over the forecast time period as well. This regional dominance can be attributed to the regional presence of major pharmaceutical and biotechnology companies, increasing adoption of the latest technologies, and established healthcare infrastructure. The Asia Pacific region is expected to record high growth in the biomarkers market globally in the years ahead. The growing support of the regional governments for drug discovery and development programs and large patient pool are the major factors boosting the biomarkers market development in the Asia Pacific.
Some key players in the global biomarkers market are
Agilent Technologies, F. Hoffmann-La Roche, Epigenomics, Abbott, Thermo Fisher Scientific, Johnson & Johnson, Siemens Healthcare, Bio-Rad Laboratories, and Qiagen. The aggregate investments by the major companies are made in their R&D activities to improve the product portfolio, which is projected to boost the biomarkers market growth in the future. For instance, in November 2016, Thermo Fisher Scientific added four items in its product portfolio for cancer research. These new products include the Oncomine Immune Response Research Assay, which is designed to cross-examine microenvironment of a tumor and identify prognostic biomarkers for immunotherapy clinical research trials.
The global biomarkers market segmented as follows:
Global Biomarkers Market: Biomarker Type Analysis
- Safety Biomarkers
- Efficacy Biomarkers
- Validation Biomarkers
Global Biomarkers Market: Application Analysis
- Diagnostic
- Drug Discovery and Development
- Personalized Medicine
- Others
Global Biomarkers Market: Technology Analysis
- Cancer
- Cardiovascular Diseases
- Neurological Diseases
- Immunological Diseases
- Others
Global Biomarkers Market: Regional Analysis
- North America
- The U.S.
- Europe
- UK
- France
- Germany
- Asia Pacific
- China
- Japan
- India
- Latin America
- Brazil
- Middle East and Africa